- Cambridge Nutritional Science
- 27 May 2025 10:22:02
Source: Sharecast
Cambridge Nutritional said total income was expected to be roughly £11.1m, representing a 12% increase on the prior year, including £2.5m of exceptional income recognised as a result of the successful outcome from its DHSC settlement. However, revenue excluding exceptional and other income was £8.3m, down from £9.8m in FY24.
Gross profit margins were seen at approximately 65%, up from 61.9% a year earlier, while adjusted underlying earnings were expected to have doubled to £400,000 and pre-tax profits were seen at £1.6m, improving from FY24's pre-tax loss of £750,000. Net cash balances slipped by £500,000 to £4.9m.
Looking forward, Cambridge Nutritional said the new financial year had "started positively" as its growing revenue pipeline started to flow through, which it said was "early evidence" of the more target focused delivery of the revenue strategy for FY26 and was aided by a solid sales position completed in the UK in FY25.
Chief executive James Cooper said: "I am pleased with our performance in 2025, delivering good solid profit even before we see the benefit of our new sales pipeline coming through its long sales cycle. It is a very exciting time for food sensitivity testing in a global market when gut health diagnostics are showing signs of growth. I want to personally thank all our people and acknowledge all their hard work and effort in the last year. Looking forward, Cambridge Nutritional Sciences is in a very strong position from a product and team perspective, with significant cash resources and the prospects for revenue and profitability growth in 2026 and beyond."
As of 1020 BST, Cambridge Nutritional shares had rallied 15.51% to 3.29p.
Reporting by Iain Gilbert at Sharecast.com